Baird Capital Deal Named Corporate/Strategic Acquisition of the Year by The M&A Advisor

CHICAGO, March 20, 2014

Baird Capital portfolio company MedPlast Inc.’s October 2013 acquisition of UK-based Orthoplastics has been named the “Corporate/Strategic Acquisition of the Year” in the $75 million–$100 million category by The M&A Advisor. Award winners will be acknowledged at the 6th Annual International M&A Advisor Awards Gala celebration on April 8 at the New York Athletic Club.

“We are very pleased to see this strategic acquisition recognized in this way, especially given Orthoplastics importance for MedPlast in expanding the company’s reach within the global healthcare market,” said Andrew Brickman, Partner in Baird Capital’s U.S. Private Equity group. “The combination of MedPlast and Orthoplastics represents a significant step in building a leading global healthcare platform and provides our customers with comprehensive medical device capabilities.”

About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Since 1989, Baird Capital’s U.S. Private Equity group has invested in growing and profitable lower-middle-market companies in the Business Services, Healthcare, and Industrial and Consumer Products sectors. Having invested in more than 270 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in Asia, a proactive portfolio operations team and a deep network of relationships which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit

For additional information, contact:

Angela Pittman Taylor
Baird Public Relations

Andrew Brickman
Baird Capital